On January 3, 2022, Bradley L. Radoff and the Radoff Foundation announced that they have entered into a Cooperation Agreement with Enzo Biochem, Inc. Bradley L. Radoff stated that pursuant to the Cooperation Agreement, the Company agreed, among other things, to immediately appoint Hamid Erfanian and Bradley L. Radoff to the Board of Directors as Class I directors with terms expiring at the Company's upcoming 2021 annual meeting of shareholders, whereat they will be nominated for re-election, in place of Dov Perlysky and Rebecca Fischer, who each resigned from the Board on January 3, 2022. In addition, Bradley L. Radoff stated that at the 2021 annual meeting the Company will propose an amendment to its Charter and seek shareholder approval to declassify the Board such that, if passed, directors standing for election at and subsequent to the 2021 annual meeting will stand for election to 1-year terms. Pursuant to the Cooperation Agreement, the Radoff Group withdrew its nomination of director candidates for election to the Board at the 2021 Annual Meeting and is subject to certain customary standstill restrictions, the Radoff Group also agreed to vote its Shares (a) in favor of all directors nominated by the Board for election, (b) in favor of the declassification proposal and (c) otherwise in accordance with the Board's recommendations with respect to any other matter presented to shareholders of the Company.